- Home
- NA vs VANI Comparison
NA vs VANI Comparison
Compare NA & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NA | VANI |
|---|---|---|
| Founded | 2019 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.0M | 91.9M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NA | VANI |
|---|---|---|
| Price | $3.21 | $1.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 39.9K | ★ 512.7K |
| Earning Date | 03-24-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,369,693.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.75 | $0.91 |
| 52 Week High | $31.48 | $1.92 |
Technical Indicators
Market Signals| Indicator | NA | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 40.53 | 45.69 |
| Support Level | $2.81 | $1.30 |
| Resistance Level | $3.84 | $1.55 |
| Average True Range (ATR) | 0.29 | 0.11 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 30.84 | 19.12 |
Price Performance
Historical ComparisonAbout NA Nano Labs Ltd
Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.